Canagliflozin (CG) is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) for the treatment of type 2 diabetes mellitus (T2DM), which can reduce glycemia as well as blood pressure, body weight and albuminuria in people with diabetes [3,4]. This evidence concerns the gene SLC5A2 and diabetes mellitus.